Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer  Krista J. Hachey, MD, Philip D. Hewes, MD, MPH, Liam P. Porter, BS, Douglas G. Ridyard, BS, Pamela Rosenkranz, RN, MEd, David McAneny, MD, Hiran C. Fernando, MBBS, Virginia R. Litle, MD  The Journal of Thoracic and Cardiovascular Surgery  Volume 151, Issue 1, Pages 37-44.e1 (January 2016) DOI: 10.1016/j.jtcvs.2015.08.039 Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Proposed clinical application of the Caprini venous thromboembolism risk assessment model throughout the preoperative, postoperative, and hospital discharge phases for lung resection patients. DVT, Deep vein thrombosis; IVC, interior vena cava; VTE, venous thromboembolism; LMWH, low molecular weight heparin. *Integration into the electronic medical record recommended for access throughout perioperative period. †Enoxaparin 40mg daily or weight-based dosing. Assess bleeding risks prior to prescribing extended course anticoagulation. ‡Anticoagulation duration per ASCO recommendations15. The Journal of Thoracic and Cardiovascular Surgery 2016 151, 37-44.e1DOI: (10.1016/j.jtcvs.2015.08.039) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

Distribution of patients and overall venothromboembolism (VTE) incidence by risk category. Values are n (%), unless otherwise indicated. “VTE patients” had a VTE event; “No-VTE patients” did not have a VTE event. The Journal of Thoracic and Cardiovascular Surgery 2016 151, 37-44.e1DOI: (10.1016/j.jtcvs.2015.08.039) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions